Myriad Genetics (MYGN) Common Equity (2010 - 2026)

Myriad Genetics (MYGN) has reported Common Equity for 17 consecutive years, with $337.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 52.14% year-over-year to $337.4 million; the TTM figure through Mar 2026 stood at $337.4 million (down 52.14% YoY), while the FY2025 annual figure was $368.0 million, down 47.51% from the prior year.
• Common Equity retreated to $337.4 million in Q1 2026 per MYGN's latest filing, from $368.0 million in the prior quarter.
• Across five years, Common Equity topped out at $950.1 million in Q1 2022 and bottomed at $337.4 million in Q1 2026.
• Historically, Common Equity has averaged $696.6 million across 5 years, with a median of $735.2 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity rose 8.56% — and 2026, when it tumbled 52.14%.
• Myriad Genetics' Common Equity stood at $885.8 million in 2022, then decreased by 11.58% to $783.2 million in 2023, then declined by 10.48% to $701.1 million in 2024, then sank by 47.51% to $368.0 million in 2025, then dropped by 8.32% to $337.4 million in 2026.
• Business Quant data shows MYGN's Common Equity at $337.4 million in Q1 2026, $368.0 million in Q4 2025, and $372.8 million in Q3 2025.